Comment: Senate’s drug-price reforms would limit access
A proposal in the Democrats’ reconcilation bill could force some providers to close or limit medications.
The Cantwell-Grassley PBM Bill is Needed, But More Can Be Done
A proposal could prohibit a PBM from “spread pricing” and “pharmacy clawbacks” unless it passes all rebates and concessions to health plans and discloses important pricing information.
Drug Pricing Plan Faces Industry Gripes as Senate Reconvenes
A new Senate proposal could hinder drugmakers from producing generic version of traditional drugs.
How a Formulary Change and a Few Tweets Led to a HIPAA Complaint
Patient and patient advocate Beth Waldron used her social media platform to criticize CVS Caremark’s removal of Eliquis (apixaban) from its national formulary. CVS took notice.
Karen Ferguson: Pharmacy benefit managers must be reined in
Karen Ferguson is the Practice Administrator at Arthritis Northwest, and co-founder/CEO of Discus Analytics, Inc., a health care company specializing in the capture, analysis and application of actionable clinical data. She is also the founder of Our Stories Rx.
Opinion: Addressing rising drug costs for patients
Ryan Oftebro, CEO of Kelley-Ross Pharmacy Group in Seattle, and President of the Washington State Pharmacy Association.